Back to News
Market Impact: 0.15
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Source: GlobeNewswire
Healthcare & BiotechPatents & Intellectual Property
The article states that covered applications target potential therapies for mental-health conditions, including depression and PTSD, as well as substance-use disorders. It provides no clinical data, regulatory milestone, financial terms, or commercialization timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
- J&J presents patient data on nipocalimab for Sjögren’s disease
- Rent-a-grandchild: Businesses offering companions to elderly grow in India